WEBMD HEALTH CORP. NEW YORK, July 24, 2017 /PRNewswire/ -- WebMD Health Corp. (NASDAQ: WBMD), the leading source of health information, today announced preliminary financial results for the three months ended June 30, 2017.
Preliminary Results for the Three Months Ended June 30, 2017
WebMD expects that its second quarter revenue, net income and Adjusted EBITDA will be above previously stated financial guidance for the second quarter.
-- Revenue for the second quarter is expected to be approximately $176
million, an increase of approximately 5% from the prior year period.
Prior financial guidance for the quarter was $170 million to $173
million.
-- Net income for the second quarter is expected to be approximately $18.9
million, an increase of approximately 6% from the prior year period.
Prior financial guidance for the quarter was $16.9 million to $18.5
million. Net income for the second quarter includes an after-tax expense
of $1.3 million, related to third-party costs incurred in connection
with the review of strategic alternatives and an after-tax gain of
approximately $0.3 million related to the sale of property.
-- Adjusted EBITDA for the second quarter is expected to be approximately
$54 million, an increase of approximately 8% from the prior year period.
Prior financial guidance for the quarter was $49 million to $51 million.
This information is preliminary and subject to the completion of WebMD's normal closing process and finalization of quarterly financial and accounting procedures. WebMD is not planning to hold a conference call regarding second quarter results.
About WebMD
WebMD Health Corp. (NASDAQ: WBMD) is the leading provider of health information services, serving consumers, physicians, healthcare professionals, employers, and health plans through our public and private online portals, mobile platforms and health-focused publications.
The WebMD Health Network includes WebMD.com, Medscape.com, MedicineNet.com, eMedicineHealth.com, RxList.com, OnHealth.com, Medscape Education (Medscape.org) and other WebMD owned sites and apps.
*****************************
All statements contained in this press release, other than statements of historical fact, are forward-looking statements, including those regarding preliminary second quarter results (which reflect what WebMD currently expects to report and are subject to adjustment). These statements speak only as of the date of this press release, are based on our current plans and expectations, and involve risks and uncertainties that could cause actual future events or results to be different than those described in or implied by such forward-looking statements. Except as required by applicable law or regulation, we do not undertake any obligation to update our forward-looking statements to reflect future events or circumstances.
*************************************
This press release, and the accompanying table, include both financial measures in accordance with accounting principles generally accepted in the United States of America, or GAAP, as well as certain non-GAAP financial measures. A reconciliation of net income (a GAAP financial measure) to Adjusted EBITDA (a non-GAAP financial measure) and an "Explanation of Non-GAAP Financial Measures" are attached to this press release.
*****************************
WebMD®, Medscape®, CME Circle®, Medpulse®, eMedicine®, MedicineNet®, theheart.org® and RxList® are among the trademarks of WebMD Health Corp. or its subsidiaries.
WEBMD HEALTH CORP.
PRELIMINARY FINANCIAL INFORMATION
(in millions, except per share amounts)
(unaudited)
Quarter Ended
June 30, 2017
(Preliminary)
------------
Revenue $176.0
======
Net income $18.9
=====
Interest, taxes, non-cash and other items
(a)
Interest income (1.9)
Interest
expense 7.0
Income tax
provision 11.9
Depreciation
and
amortization 7.6
Non-cash
stock-based
compensation 8.9
Transaction
expense 2.1
Other income (0.6)
Earnings before interest, taxes, non-cash
and other items
("Adjusted
EBITDA") (b) $53.9
Net income per common share:
Basic $0.51
=====
Diluted $0.43
=====
Weighted-average shares outstanding used
in computing
income per
common share:
Basic 37.1
====
Diluted 54.4
====
(a) Reconciliation
of net income
to Adjusted
EBITDA.
See Annex A-
Explanation of
Non-GAAP
Financial
(b) Measures.
Additional information regarding preliminary results for the quarter ended
June 30, 2017:
- Transaction expense
represents professional
fees incurred in
connection with the
process conducted by the
Board of Directors to
explore strategic
alternatives
for the Company.
- Other income represents a
gain on the sale of
property.
ANNEX A
Explanation of Non-GAAP Financial Measures
The accompanying WebMD Health Corp. press release and attachment include both financial measures in accordance with U.S. generally accepted accounting principles, or GAAP, as well as non-GAAP financial measures. The non-GAAP financial measures represent earnings before interest, taxes, non-cash and other items (which we refer to as "Adjusted EBITDA"). Adjusted EBITDA should be viewed as supplemental to, and not as an alternative for net income or loss calculated in accordance with GAAP (referred to below as "net income"). The attachment to the press release includes a reconciliation of net income to Adjusted EBITDA.
Adjusted EBITDA is used by our management as an additional measure of our company's performance for purposes of business decision-making, including developing budgets, managing expenditures, and evaluating potential acquisitions or divestitures. Period-to-period comparisons of Adjusted EBITDA help our management identify additional trends in our company's financial results that may not be shown solely by period-to-period comparisons of net income. In addition, we may use Adjusted EBITDA in the incentive compensation programs applicable to some of our employees in order to evaluate our company's performance. Our management recognizes that Adjusted EBITDA has inherent limitations because of the excluded items, particularly those items that are recurring in nature. In order to compensate for those limitations, management also reviews the specific items that are excluded from Adjusted EBITDA, but included in net income, as well as trends in those items. The amounts of those items are set forth, for the applicable periods, in the reconciliations of Adjusted EBITDA to net income that accompany our press releases and disclosure documents containing non-GAAP financial measures, including the reconciliation contained in the accompanying press release attachment.
We believe that the presentation of Adjusted EBITDA is useful to investors in their analysis of our results for reasons similar to the reasons why our management finds it useful and because it helps facilitate investor understanding of decisions made by management in light of the performance metrics used in making those decisions. In addition, as more fully described below, we believe that providing Adjusted EBITDA, together with a reconciliation of Adjusted EBITDA to net income, helps investors make comparisons between our company and other companies that may have different capital structures, different effective income tax rates and tax attributes, different capitalized asset values and/or different forms of employee compensation. However, Adjusted EBITDA is intended to provide a supplemental way of comparing our company with other public companies and is not intended as a substitute for comparisons based on net income. In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP measures to evaluate their financial performance. Investors should pay close attention to the specific definition being used and to the reconciliation between such measures and the corresponding GAAP measures provided by each company under applicable SEC rules.
The following is an explanation of the items excluded by us from Adjusted EBITDA but included in net income:
-- Depreciation and Amortization. Depreciation and amortization expense is
a non-cash expense relating to capital expenditures and intangible
assets arising from acquisitions that are expensed on a straight-line
basis over the estimated useful life of the related assets. We exclude
depreciation and amortization expense from Adjusted EBITDA because we
believe that (i) the amount of such expenses in any specific period may
not directly correlate to the underlying performance of our business
operations and (ii) such expenses can vary significantly between periods
as a result of new acquisitions and full amortization of previously
acquired tangible and intangible assets. Accordingly, we believe that
this exclusion assists management and investors in making
period-to-period comparisons of operating performance. Investors should
note that the use of tangible and intangible assets contributed to
revenue in the periods presented and will contribute to future revenue
generation and should also note that such expense will recur in future
periods.
-- Stock-Based Compensation Expense. Stock-based compensation expense is a
non-cash expense arising from the grant of stock-based awards to
employees. We believe that excluding the effect of stock-based
compensation from Adjusted EBITDA assists management and investors in
making period-to-period comparisons in our company's operating
performance because (i) the amount of such expenses in any specific
period may not directly correlate to the underlying performance of our
business operations and (ii) such expenses can vary significantly
between periods as a result of the timing of grants of new stock-based
awards, including grants in connection with acquisitions. Additionally,
we believe that excluding stock-based compensation from Adjusted EBITDA
assists management and investors in making meaningful comparisons
between our company's operating performance and the operating
performance of other companies that may use different forms of employee
compensation or different valuation methodologies for their stock-based
compensation. Investors should note that stock-based compensation is a
key incentive offered to employees whose efforts contributed to the
operating results in the periods presented and are expected to
contribute to operating results in future periods. Investors should
also note that such expenses will recur in the future.
-- Interest Income and Expense. Interest income is associated with the
level of marketable debt securities and other interest bearing accounts
in which we invest, and interest expense is related to our company's
capital structure (including non-cash interest expense relating to our
convertible notes). Interest income and expense varies over time due to
a variety of financing transactions and due to acquisitions and
divestitures that we have entered into or may enter into in the future.
We have, in the past, issued convertible debentures, repurchased shares
in cash tender offers and repurchased shares and convertible debentures
through other repurchase transactions, and completed the divestiture of
certain businesses. We exclude interest income and interest expense
from Adjusted EBITDA (i) because these items are not directly
attributable to the performance of our business operations and,
accordingly, their exclusion assists management and investors in making
period-to-period comparisons of operating performance and (ii) to assist
management and investors in making comparisons to companies with
different capital structures. Investors should note that interest
income and expense will recur in future periods.
-- Income Tax Provision (Benefit). We maintain a valuation allowance on a
portion of our net deferred tax assets (including our net operating loss
carryforwards), the amount of which may change from quarter to quarter
based on factors that are not directly related to our results for the
quarter. The valuation allowance is either adjusted through the
statement of operations or additional paid-in capital. The timing of
such adjustments has not been consistent and as a result, our income tax
expense can fluctuate significantly from period to period in a manner
not directly related to our operating performance. We exclude the
income tax provision (benefit) from Adjusted EBITDA (i) because we
believe that the income tax provision (benefit) is not directly
attributable to the underlying performance of our business operations
and, accordingly, its exclusion assists management and investors in
making period-to-period comparisons of operating performance and (ii) to
assist management and investors in making comparisons to companies with
different tax attributes. Investors should note that income tax
provision (benefit) will recur in future periods.
-- Other Items. We engage in other activities and transactions that can
impact our net income. In recent periods, these other items included,
but were not limited to: (i) gain on investments; (ii) settlements of
litigation or claims; (iii) loss on repurchases of our convertible
notes; (iv) severance expense; (v) gain on sale of property; and (vi)
legal fees and other expenses incurred in connection with the process
conducted by our Board of Directors to explore strategic alternatives
for our company. We exclude these other items from Adjusted EBITDA
because we believe these activities or transactions are not directly
attributable to the performance of our business operations and,
accordingly, their exclusion assists management and investors in making
period-to-period comparisons of operating performance. Investors should
note that some of these other items may recur in future periods.
View original content:http://www.prnewswire.com/news-releases/webmd-provides-preliminary-second-quarter-financial-results-300492705.html
SOURCE WebMD Health Corp.
